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BAY 43-9006 is a novel dual-action Raf kinase and vascular endothelial growth factor receptor (VEGFR) inhibitor that targets tumour
cell proliferation and tumour angiogenesis. This Phase I study was undertaken to determine the safety profile, maximum tolerated
dose (MTD), dose-limiting toxicities (DLTs), pharmacokinetics, and tumour response profile of oral BAY 43-9006 in patients with
advanced, refractory solid tumours. BAY 43-9006 was administered daily for repeated cycles of 21 days on/7 days off. A total of 44
patients were enrolled at doses from 50 to 800mg b.i.d. Pharmacokinetic profiles of BAY 43-9006 in plasma were determined during
the first treatment cycle. The most frequently reported adverse events over multiple cycles were gastrointestinal (75%), dermatologic
(71%), constitutional (68%), pain (64%), or hepatic (61%) related. A MTD of 400mg b.i.d. BAY 43-9006 was defined. BAY 43-9006
was absorbed rapidly; steady-state conditions were reached within 7 days. BAY 43-9006 exposure increased nonproportionally with
increasing dose. In all, 32 patients were evaluated for tumour response: 15 patients showed tumour progression, 16 patients
experienced stable disease (46 months in eight patients), and one patient with renal cell carcinoma achieved a partial response. BAY
43-9006 given for 21 days with 7 days off treatment was safe, well tolerated, and showed antitumour activity.
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Activation of receptor tyrosine kinases (RTKs) by cytokines or
growth factors initiates a protein-kinase-mediated cascade of
molecular events that ultimately leads to control of cell growth and
survival. The growth factor receptors activate the cellular Ras
proteins, which interact with and activate the Raf protein kinase.
The Raf protein kinase activates the Raf/MEK/ERK pathway that
initiates cell proliferation. Overactivation of this pathway has been
observed in many human malignancies and, therefore, compo-
nents of this cascade are attractive targets for anticancer therapies
(Hoshino et al, 1999; Avruch et al, 2001).
Raf proteins are not solely key downstream effector molecules of
Ras; recent work suggests a direct role for Raf in the development
and maintenance of cancer. Overexpression of constitutively active
c-Raf is sufficient for NIH 3T3 cellular transformation (Kerkhoff
and Rapp, 1997). Mutations in the BRAF gene derived from human
cancer cell lines and human primary cancers can affect cellular
transformation of NIH 3T3 cells, and Raf can exert tumorigenic
effects independent of Ras (Davies et al, 2002; Rajagopalan et al,
2002). Furthermore, it has been suggested that Raf signalling is
necessary for tumour neovascularisation, which is essential for
tumour survival, growth, and metastasis (Bergers et al, 2003).
BAY 43-9006 is a potent, small-molecule inhibitor of c-Raf and
wild-type and mutant V599E B-Raf (Wilhelm et al, 2004). BAY
43-9006 inhibits c-Raf-mediated ERK phosphorylation in vitro and
decreases endogenous phosphorylated ERK in tumour cell lines
containing either mutant Ras or mutant B-Raf. BAY 43-9006 also
targets the vascular endothelial growth factor (VEGF) receptors,
VEGFR-2 and VEGFR-3, and platelet-derived growth factor
receptor-b (PDGFR-b) – key RTKs involved in tumour progression
and angiogenesis (Wilhelm et al, 2004).
In human tumour xenograft models, BAY 43-9006 significantly
delayed tumour growth of colon, pancreatic, and non-small-cell
lung cancer (NSCLC) models containing either B-Raf or K-Ras
mutations (Wilhelm et al, 2004). BAY 43-9006 also slowed tumour
growth of ovarian cancer derived from the SKOV-3 cell line, which
contains wild-type K-Ras but overexpresses epidermal growth
factor and HER-2 receptors (Gianpaolo-Ostravage et al, 2001;
Lyons et al, 2001). Administration of BAY 43-9006 to mice with
human colon tumours (HT-29 or Colo-205) or MBA-MD-231
human breast tumour xenografts significantly reduced tumour
neovascularisation, as measured by decreased CD31-positive
microvessel density (Wilhelm et al, 2004).
The anticancer activity of BAY 43-9006 appears to be cytostatic,
requiring continued drug exposure for tumor growth inhibition. In
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spreclinical studies, tumor growth was inhibited in the presence of
the drug, but returned to baseline growth rates upon treatment
cessation. In order to achieve a balance between minimising time
off BAY 43-9006 and avoiding potential toxicity associated with
extended exposure, four Phase I studies were initiated to
determine the most favorable and effective dosing regime
(Strumberg et al, 2003).
This Phase I trial was conducted to determine the dose-limiting
toxicity (DLT), maximum tolerated dose (MTD), and the safety
and pharmacokinetics of BAY 43-9006 administered for 21
consecutive days, followed by 7 days off treatment, in patients
with refractory solid tumours.
PATIENTS AND METHODS
Patient selection
A total of 44 patients with advanced, refractory solid tumours were
enrolled between December 2000 and December 2002. Eligible
patients were at least 18 years of age and had failed curative
measures, an Eastern Cooperative Oncology Group (ECOG)
performance status of p2 and a life expectancy of X12 weeks.
These patients also had adequate bone marrow (haemoglobin
X10mgdl
 1, platelets 4100000mm
 3, neutrophils
X2000mm
 3), hepatic (bilirubin p1.5 upper limit of normal
(ULN), alanine aminotransferase (ALT), and aspartate amino-
transferase (AST) p5 ULN), and renal (serum creatinine
p1.5 ULN or calculated creatinine clearance 460mlmin
 1
function.
Patients with primary or metastatic brain or meningeal tumours
were excluded from the study, as were patients with clinically
evident congestive heart failure, serious cardiac arrhythmias, or
symptoms of coronary heart disease or ischaemia. Patients with
serious active infections, and pregnant or lactating women were
also excluded from the study. Enrolled patients had not received
immunotherapy or chemotherapy within 4 weeks of study entry, or
radiotherapy within 3 weeks of study entry.
All patients received information on the purpose and conduct of
this study, and provided written, informed consent in accordance
with federal and institutional guidelines. This study received
institutional ethical approval and was conducted in accordance
with the Declaration of Helsinki and good clinical practice.
Treatment plan
This was an open-label, noncontrolled, single-centre (Brussels,
Belgium) dose-escalation study in which groups of three to six
patients received oral BAY 43-9006 administered in repeated cycles
of 21 days on drug followed by a 7-day rest period. The first two
groups received 50mg BAY 43-9006 once daily – either 50mg
every 5 days, or 50mg every other day (henceforth referred to as
50mg combination (COMB)). The remaining groups received BAY
43-9006 twice daily (b.i.d.) at a dose of 100, 200, 300, 400, 600, or
800mg for 21 consecutive days.
Three patients were initially enrolled in each group (Figure 1).
Groups were treated according to a standardised dose-escalation
scheme, depending on the worst toxicity experienced by patients
enrolled at the prior dose level, and the clinical significance of that
toxicity. In the absence of DLT within the first 28 days, the next
group of three patients was enrolled at the next dose level. If DLT
was observed in at least two patients enrolled in a given group
within the first 28 days, the MTD was defined as the previous dose
level. If only one patient experienced DLT, a further three patients
were enrolled in that group. If DLT was observed in at least one
more of these six patients, the MTD was defined as the previous
dose level. If none of the additional patients in this expanded
cohort experienced a DLT, dose escalation continued. Once the
MTD was established, up to four additional patients could be
enrolled at the MTD level (up to 10 patients in total) to obtain
additional safety data at the recommended dose.
Adverse events (AEs) possibly or probably related to the study
drug were considered DLTs if they met any of the following
criteria: nonhaematological toxicity (excluding alopecia) of at least
grade 3 severity according to version 2.0 of the National Cancer
Institute Common Toxicity Criteria (NCI-CTC); neutropenia of
NCI-CTC grade 4 lasting for X4 days; thrombocytopenia of at least
NCI-CTC grade 3. Patients in any cohort who experienced a DLT
before the end of a treatment cycle had the number of DLT-free
Enrol three patients 
No DLT in any 
patient within 
first 28 days 
DLT in one 
patient within 
first 28 days 
DLT in2 
patients within 
first 28 days 
Expand to 
six patients 
MTD defined. 
Enrol4 additional 
patients at the 
MTD 
DLT in1 
further patient  
No further DLT 
Escalate to next dose level 
Increase dose in 
50 mg increments  Increase by doubling 
prior dose 
Figure 1 Dose-escalation schema.
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sdays recorded. Following the appearance of a DLT, study
medication was withheld until toxicity resolved or returned to a
severity pgrade 2, or until the principle investigator considered it
appropriate to resume treatment. The recovery period was also
noted for each patient. Patients resumed BAY 43-9006 at the initial
dose, but an intermittent dosing schedule was utilised, depending
on the duration of DLT-free days and the DLT recovery time,
based on an algorithm. If patients experienced a DLT on this
intermittent schedule, BAY 43-9006 was withheld until recovery,
after which time the patient received BAY 43-9006 at the next lower
dose level.
Patient evaluation
Pretreatment evaluations took place 7 days before enrolment, and
included physical examinations (weight, height, vital signs), ECOG
performance status, documentation of all measurable or evaluable
disease, recording of concurrent medications, routine laboratory
evaluations (complete blood counts, platelets, differential counts,
biochemistry, and clotting times), and pregnancy tests for women.
Pretreatment studies also included an electrocardiogram (ECG)
within the 28 days before enrolment.
Physical examinations were performed on day 1 of each
treatment cycle, haematological laboratory evaluations twice
weekly during the treatment period, and biochemical evaluations
twice weekly during the first cycle, and twice per cycle thereafter.
Clinical tumour measurements were carried out as part of the
physical examination. Scans and X-rays to document the disease
were obtained every 8 weeks, and were compared with those
obtained prior to treatment. Tumour response was evaluated
according to the Response Evaluation Criteria in Solid Tumours
(RECIST) system (Therasse et al, 2000). Complete or partial
responses (CR or PR) required a confirmatory scan at least 4 weeks
later. For an assessment of stable disease (SD), documentation of
SD was required at least once X4 weeks from baseline.
Safety
All patients who received at least one dose of BAY 43-9006 were
included in the safety analysis. Adverse events were assessed at the
end of each cycle and up to 30 days after the last dose of study
medication, and were graded according to the NCI-CTC version 2
(Trotti et al, 2000). Patients with grade 3/4 treatment-related
toxicities were required to improve to pgrade 2 before resuming
treatment. If tumour progression occurred, treatment with the
study medication was discontinued, and a final visit took place
within 2 weeks.
Pharmacokinetics
Patients who completed at least one cycle of BAY 43-9006 and had
no missing pharmacokinetic measurements were valid for
pharmacokinetic analysis. Blood samples from patients in the
100mg b.i.d. group or higher were collected on days 1, 7, and 21 of
the first cycle. Blood samples (2ml aliquots) were collected at 0
(predose), 2, 3, 4, 6, 12, and 24h after study drug administration.
When BAY 43-9006 was given b.i.d., blood was collected up to 12h
after administration. After the last dosage on day 21, two
additional samples were collected 48 and 96h later.
Plasma was removed from the blood samples following
centrifugation, and stored at  701C. A validated LC-MS/MS
method with multiple reaction monitoring was used for determi-
nation of BAY 43-9006 plasma concentration with lower limits of
quantification (LOQ) at 1.0, 2.4, or 100mgl
 1 depending on the
method used. Method validation was performed in accordance
with internationally accepted requirements. Mean accuracy for
quality control samples ranged from 91.7 to 104.9%, and mean
precision from 0.7 to 13.5% for all methods used.
Plasma pharmacokinetic parameters – area under the curve
(AUC), maximum concentration (Cmax), time to maximum
concentration (tmax), and apparent terminal half-life (t1/2) – for
BAY 43-9006 were calculated by noncompartmental methods using
KINCALC (a program developed by Bayer HealthCare). This
program uses a log-linear trapezoidal method for determining the
AUC values. Pharmacokinetic parameters were analysed with
descriptive statistics. Plasma concentration–time courses of BAY
43-9006 (calculated if two-thirds or more of the individual values
were above the LOQ) are presented as geometric means.
RESULTS
Patients’ characteristics
Patients received BAY 43-9006 50mg once every 5 days or every
other day (seven patients), or 100mg b.i.d. (four patients), 200mg
b.i.d. (three patients), 300mg b.i.d. (five patients), 400mg b.i.d. (10
patients), 600mg b.i.d. (12 patients), and 800mg b.i.d. (three
patients) for 21 consecutive days followed by 7 days off treatment.
Patients’ baseline characteristics are shown in Table 1. All patients
on study were Caucasian. The most common forms of cancer were
colon carcinoma (34%), breast cancer (16%), and kidney
carcinoma (16%); all patients presented with metastatic cancer.
Before study entry, all patients had been treated with systemic
therapy, 41 (93%) with surgery and 22 (50%) with radiotherapy
(Table 1). Grade 3 hepatic abnormalities were recorded at baseline
in one patient each from the 100mg b.i.d., 200mg b.i.d., 300mg
b.i.d., and 600mg b.i.d. groups, and in three patients in the 400mg
b.i.d. group. Five of these patients had liver metastases at baseline.
Patient outcomes
A total of 42 (95%) patients discontinued the study, most
commonly because of disease progression (68%) or AEs (18%).
All nine patients who discontinued because of AEs were from the
Table 1 Demographic and clinical characteristics of patients treated on
study
Characteristic Number of patients
No. of patients (evaluable) 44
Median age (range), years 58 (42–79)
Gender (male:female) 25:19
ECOG performance status (n (%))
0 12 (27)
1 30 (68)
2 2 (5)
Previous therapy (n (%))
Surgery 41 (93)
Systemic therapy 44 (100)
Radiotherapy 22 (50)
Tumour types
Colon 15 (34)
Breast 7 (16)
Kidney 7 (16)
Ovary 1 (2)
Liver 1 (2)
Gastrointestinal (other) 2 (5)
Head and Neck 1 (2)
Lung 1 (2)
Melanoma 2 (5)
Unknown 5 (11)
Other 2 (5)
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sX300mg b.i.d. groups. Of these nine patients, only one
discontinued as a result of a serious event (oedema of the uvula)
related to study medication (600mg b.i.d. dose group). Six (14%)
patients died while on study medication due to tumour progres-
sion; none of the events resulting in death was considered
treatment related.
Dose escalation and modification
No nonhaematological DLT occurred at the 50 or 100mg b.i.d.
dose levels. One of three patients (33%) developed DLT at the
800mg b.i.d. dose level, and seven of 12 patients (58%) enrolled at
600mg developed DLT. An additional group treated with BAY 43-
9006 400mg b.i.d. was examined because of the high proportion of
serious drug-related AEs in the 600mg b.i.d. group, and the lack of
Xgrade 3 toxicities in the 300mg b.i.d. group (except one patient
with fatigue). Of the first three patients treated at 400mg b.i.d., one
had drug-related toxicity Xgrade 3. Three additional patients were
enrolled in this group, and no DLTs were observed, so the group
was increased to 10 patients.
Treatment and dose exposure
The overall median duration of treatment with BAY 43-9006 was 42
days (Table 2). The duration of treatment varied widely, ranging
from 1 to 261 days of treatment. The greatest time on study drug
was in the 600mg b.i.d. (starting dose) group: 450% of patients
received more than three cycles, for a median treatment duration
of 95 days (Table 2). Of note, the dose for nine of 12 (75%) of these
patients treated at the starting dose of 600mg b.i.d. was reduced to
400mg b.i.d. until the end of therapy. Of these nine patients, six
(67%) experienced DLTs before their dose was reduced to 400mg
b.i.d. BAY 43-9006. Two of the three patients assigned to 800mg
b.i.d. received a dose reduction: one patient to 600mg b.i.d. 5 days
after treatment initiation and prior to the patient being
discontinued due to no clinical benefit (total one cycle); one
patient to 600mg b.i.d. (four cycles) and then to 400mg b.i.d. (five
cycles) due to toxicity (total of 10 cycles received).
Safety
All 44 patients were evaluated for safety and AEs were reported for
all patients. The most frequently reported treatment-emergent
toxicities over multiple cycles were gastrointestinal (75% of
patients), dermatologic/skin disorders (71%), constitutional symp-
toms (68%), pain (64%), and hepatic disorders (61%). Individual
AEs occurring in X20% of patients were anorexia, nausea,
diarrhoea, and stomatitis/pharyngitis for the gastrointestinal
toxicities; hand–foot skin reaction (HFS), rash/desquamation,
pruritus, and alopecia for dermatological toxicities; and fatigue
and fever for constitutional symptoms. Other pain (excluding
abdominal, bone or tumour pain, headache, arthralgia, or myalgia)
occurred in 30% of patients, and abnormal AST, ALT, alkaline
phosphatase (ALP), and bilirubin levels were the most frequent
hepatic-related events (occurring in X20% of patients).
A total of 34 patients experienced drug-related AEs of any grade;
the most common AEs were fatigue (52% of patients), HFS (43%),
anorexia (39%), and rash/desquamation (37%). Of these drug-
related AEs, 13 (30%) were Xgrade 3. At the 400mg b.i.d. dose
level, the most common drug-related AEs were skin-related and
hepatic disorders – HFS (50%), rash/desquamation (60%), pruritus
(30%), alopecia (30%), abnormal AST (50%), ALT (50%), ALP
(30%), and bilirubin (40%). In general, drug-related events in this
group did not exceed grade 2 toxicity (Table 3). One patient in this
group experienced grade 3 fatigue, nausea, anorexia, vomiting, and
pain. All patients in the 600mg b.i.d. dose group experienced drug-
related AEs, of which seven (58%) were Xgrade 3.
Haematological toxicities (abnormal haemoglobin, total white
blood count, and platelets) were mild to moderate in severity, and
were not dose limiting. Negligible effects on granulocytes were
observed. No patient showed any change 4 grade 2 in these
parameters from baseline, except one patient in the 50mg COMB
group, whose haemoglobin changed several times from grade 1 at
baseline to grade 3 during cycles 3–7.
In the higher dosage groups, more AEs were drug related and led
to permanent discontinuation of treatment. The incidences of
fatigue, fever without neutropenia, HFS, rash/desquamation,
pruritus, diarrhoea, stomatitis/pharyngitis, sensory neuropathy,
and elevated AST, ALT, and ALP were increased in the groups
receiving 4300mg b.i.d. BAY 43-9006.
One of the most frequently observed AEs was HFS, which was
reported in 19 (43%) patients. Grade 3 HFS occurred in five (42%)
patients in the 600mg b.i.d. group. A review of patients’ medical
histories indicated that four patients had received prior anticancer
therapy with agents known to frequently cause HFS (liposomal
doxorubicin and/or capecitabine).
Maximum tolerated dose and DLT
A total of 11 patients experienced DLT: one patient each from the
50mg COMB, 300, 400, and 800mg b.i.d. groups, and seven
patients from the 600mg b.i.d. group. Dose limiting toxicities of
grade 3 dyspnoea and fatigue were reported for one of three
patients receiving 800mg b.i.d. BAY 43-9006. Seven (58%) patients
receiving 600mg b.i.d. experienced DLTs, including HFS (three
patients, two of whom also had generalised rash), and abdominal
cramping, diarrhoea, retrosternal pain, oedema of uvula, anorexia.
At 400mg b.i.d., only one out of 10 patients developed DLT (grade
3 fatigue, anorexia, vomiting, nausea, pain). Owing to the
unacceptable incidence rate of DLTs at the 600mg b.i.d. dose,
Table 2 Exposure to BAY 43-9006 in patients with advanced, refractory solid tumours
Starting dose of BAY 43-9006
50mg COMB
a
(n¼7)
100mg b.i.d.
(n¼4)
200mg b.i.d.
(n¼3)
300mg b.i.d.
(n¼5)
400mg b.i.d.
(n¼10)
600mg b.i.d.
b
(n¼12)
800mg b.i.d.
(n¼3)
Total
(n¼44)
Median number of 28-day treatment
cycles administered (range)
2 (1–12) 2.5 (2–4) 2 (1–2) 2 (1–6) 3 (1–9) 5 (2–14)
b 1 (1–10)
No. of patients receiving more than
three cycles (n (%))
1 (14) 1 (25) 0 (0) 1 (20) 3 (30) 7 (58)
b 1 (33)
Median duration of treatment, days
(range)
c
42 (11–252) 50 (42–84) 42 (21–48) 42 (21–104) 48 (1–157) 95 (11–261)
b 21 (13–175) 42 (1–261)
aCombination of two different 50mg presentations of study drug.
bNine of these patients were reduced to 400mg b.i.d. due to toxicity.
cCalculated by adding 21 days of study
drug treatment for each completed 28-day cycle.
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s400mg b.i.d. BAY 43-9006 was determined to be the MTD, and is
the recommended dose for Phase II studies.
Pharmacokinetics
Plasma concentration–time profiles of patients in the 100mg b.i.d.
group and higher are shown in Figure 2. BAY 43-9006 is absorbed
rapidly after the first dose on day 1, and peak concentrations in
plasma occurred within 2–7h and were maintained at 12h
postdose (Figure 2A). After multiple doses of BAY 43-9006, mean
plasma concentrations were highly variable and showed no clear
dose dependency. Times of peak concentrations ranged from 0h
(before dosing) to 12h (Figure 2B and C).
Mean AUC0–12 and Cmax for BAY 43-9006 following doses of
200, 400, and 600mg b.i.d. on days 1 (first dose), 7, and 21 are
listed in Table 4. For the MTD of 400mg b.i.d., mean AUC0–12was
24.0mghl
 1 on day 1, increased to 82.7mghL
 1 by day 7 and
declined slightly to 76.5mghl
 1 by day 21. Similarly, mean Cmax
for the 400mg b.i.d. dose increased substantially between days 1
and 7 (from 3.04 to 9.90mgl
 1), with little change between days 7
and 21 (Table 4). Mean AUC0–12 and Cmax values for the other
dose levels also did not appear to increase further after day 7
(Table 4). The terminal half-life (t1/2) could be determined
following the last dose on day 21. Mean t1/2 ranged from 24 to
39h (Table 4). Comparison of the accumulation ratios for Cmax and
AUC0–12 (RA1 and RA3, respectively) indicates that steady-state
conditions were reached after 7 days of dosing. Mean RA1 and RA3
values after continuous dosing with X100mg b.i.d. BAY 43-9006
ranged from 2.6 to 6.2, and from 2.5 to 6.4, respectively, on Day 7,
and ranged from 2.0 to 6.3, and from 1.7 to 6.7, respectively, on day
21.
Response to therapy
Tumour response was evaluated in 32 (73%) patients; tumour
response evaluations were either not done or missing in six
patients, and an additional six patients were not evaluable. Of the
patients evaluable for efficacy, one patient experienced a PR, and
16 patients (50%) experienced SD as best response (Table 5). Of
the patients with SD, two had SD 412 months (600mg b.i.d.
starting dose group) and six had SD of 6–12 months (300mg b.i.d.
(n¼1); 400mg b.i.d. (n¼1); 600mg b.i.d. (n¼3); 800mg b.i.d.
starting dose group (n¼1)). In all cases, patients with SD of long
duration were switched to 400mg b.i.d. during the period of SD,
which was established as the MTD. A total of 26 (59%) patients
showed tumour progression at some time during the study, and for
15 of these patients, the best response recorded was progressive
disease (Table 5). In total, 19 (43%) patients survived at least 6
months following the first dose of BAY 43-9006, and three (7%)
patients were alive at least 12 months after the first dose was
administered.
Of the three patients assigned to BAY 43-9006 800mg b.i.d.,
two patients withdrew from the study as a result of insufficient
therapeutic effect and toxicities. The third patient had a dose
reduction following the development of AEs and experienced SD as
a best response that lasted for a median of 276 days.
Although patients who began treatment in the 600mg b.i.d.
group tended to have a longer median time to progression, they
were more likely to be treated for more than three cycles, and a
higher proportion of PR/SD best response assessments compared
with the other groups, six of the eight PR/SD patients required a
dose reduction to 400mg b.i.d. during the treatment period. One
patient with renal cell carcinoma (RCC) who received the starting
dose of 600mg b.i.d. achieved a PR lasting a total of 104 days,
during which the patient received 400mg b.i.d. for 99 days.
DISCUSSION
The results of this Phase I trial show that oral BAY 43-9006 is safe
and well tolerated when administered for 21 consecutive days
followed by a 7-day rest period. Adverse events were generally mild
to moderate and manageable with supportive medications. The
most common drug-related toxicities were fatigue, HFS, and rash.
Significant neutropenia, thrombocytopenia, and anaemia were not
observed during treatment with BAY 43-9006, suggesting that BAY
43-9006 can be combined with other anticancer agents. In
addition, life-threatening CNS, cardiac, hepatic, and renal toxi-
cities were not observed. A dose-dependent relationship was
observed for certain AEs, with a higher incidence of fatigue, HFS,
Table 3 Incidence of drug-related adverse events occurring in 410% of patients in patients with advanced, refractory solid tumours
50mg COMB
(n¼7)
100mg b.i.d.
(n¼4)
200mg b.i.d.
(n¼3)
300mg b.i.d.
(n¼5)
400mg b.i.d.
(n¼10)
600mg b.i.d.
(n¼12)
800mg b.i.d.
(n¼3)
Total
(n¼44)
Grade (%) Grade (%) Grade (%) Grade (%) Grade (%) Grade (%) Grade (%) Grade (%)
1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4 1/2 3/4
Blood/bone marrow 14 25 33 14 2
Fatigue 14 25 40 20 40 10 75 8 67 33 43 9
Hand–foot skin reaction 14 40 50 41 42 33 32 11
Rash/desquamation 14 60 50 17 33 32 5
Pruritus 14 40 30 50 8 67 32 2
Alopecia 14 25 33 20 30 50 30
Dry skin 33 33 11
Anorexia 14 25 67 60 20 10 34 8 67 34 5
Diarrhoea 20 10 42 33 16 2
Stomatitis/pharyngitis 20 20 33 33 16 2
Nausea 33 10 17 67 11 2
AST 40 50 50 33 32
ALT 50 25 33 21
ALP 30 42 18
Bilirubin 40 33 11
Sensory neuropathy 20 20 17 33 14
Other pain
a 33 20 10 17 33 14 2
Adverse events were rated according to National Cancer Institute Common Toxicity Criteria (NCI CTC) Version 2.0. ALP¼alkaline phosphatase; ALT¼alanine
aminotransferase; AST¼aspartate aminotransferase.
aOther pain excluded arthralgia, myalgia, abdominal pain and cramping, bone pain, tumour pain, and headache.
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and sensory neuropathy in the higher dose groups (4300mg
b.i.d.). The 400mg b.i.d. dose was established as the MTD after
obtaining an unacceptable incidence rate of DLT at 600mg b.i.d.
Interestingly, the AE findings in this study are similar to those
of three other parallel Phase I trials with BAY 43-9006, which
examined various dosing schedules (continuous b.i.d. dosing, 28
days on drug/7 days off, and 7 days on drug/7 days off) treating a
wide range of tumour types (Strumberg et al, 2003). Similar to the
results presented, the 400mg b.i.d. dose had the most favourable
toxicity profile of the higher dose levels evaluated, and data from
the entire Phase I programme identify 400mg b.i.d. BAY 43-9006
continuously as the recommended dose for Phase II studies
(Strumberg et al, 2003).
The pharmacokinetic profile in this study showed that BAY 43-
9006 b.i.d. is orally bioavailable in cancer patients with solid
tumours refractory to standard care. Pharmacokinetic findings for
the BAY 43-9006 dosing schedule reported here are consistent with
those obtained in the three other Phase I studies (Strumberg et al,
2003). BAY 43-9006 is rapidly absorbed after the first dose, and the
t1/2 after multiple dosing of 200–600mg b.i.d. ranged from 24 to
39h. Steady-state conditions were achieved after 7 days of dosing,
with no further accumulation after an additional 14 days of b.i.d.
dosing. These pharmacokinetic findings support 400mg b.i.d. as
the recommended Phase II dose.
Following treatment with BAY 43-9006, 50% of patients
experienced SD. Treatment with a starting dose of 600mg b.i.d.,
with a dose reduction to 400mg b.i.d., due to toxicities at 600mg
b.i.d. dose, was associated with the most favourable response
profile. Of the 16 patients with SD, duration of SD was 6–12
months in six patients, and 412 months in two patients (one with
colorectal cancer and the other patient with head and neck cancer).
Another patient with RCC experienced a PR lasting 104 days. All
five patients with prolonged SD began dosing at 600 or 800mg
b.i.d. and rapidly underwent dose reduction to 400mg b.i.d. during
the period of SD.
Renal cell carcinoma tumours are well vascularised, and recent
work links this type of cancer with mutations in the von Hippel–
Lindau tumour suppressor gene, which ultimately leads to the
overproduction of VEGF and a more aggressive tumour phenotype
(Grugel et al, 1995). BAY 43-9006 directly inhibits two VEGF
receptors, VEGFR-2 and VEGFR-3. BAY 43-9006 also targets both
Raf-1 and B-Raf kinase proteins, which promote proliferation
through the Ras mitogen pathway, and are also implicated in
Table 4 Mean pharmacokinetic parameters for BAY 43-9006 following
the first dose (day 1) and multiple (days 7 and 21) b.i.d. oral dosing
(geometric means, geometric standard deviations)
Pharmacokinetic
parameter
BAY 43-9006
dose b.i.d. (mg) n
Mean (standard
deviation) Range
Day 1
AUC0–12
(mghl
 1)
200 3 24.9 (1.39) 17.3–32.6
400 9 24.0 (1.51) 13.9–46.4
600 12 30.4 (1.68) 9.02–65.0
Cmax (mgl
 1) 200 3 3.63 (1.26) 3.00–4.70
400 10 3.04 (1.89) 0.92–7.55
600 12 4.56 (1.69) 1.58–12.1
Day 7
AUC0–12
(mghl
 1)
200 3 83.4 (1.44) 64.2–126
400 9 82.7 (1.62) 39.6–201
600 12 94.8 (1.62) 45.1–199
Cmax (mgl
 1) 200 3 9.01 (1.80) 5.58–17.4
400 9 9.90 (1.52) 5.63–23.0
600 12 11.5 (1.54) 5.96–21.8
Day 21
AUC0–12
(mghl
 1)
200 3 50.5 (1.14) 45.2–58.4
400 5 76.5 (1.28) 60.1–112
600 6 77.0 (1.55) 46.8–160
Cmax (mgl
 1) 200 3 6.33 (1.61) 4.79–11.0
400 6 10.0 (1.26) 7.46–15.1
600 8 9.24 (1.53) 4.72–16.7
t1/2 (h) 200 2 29.8 (1.14) 27.2–32.8
400 3 23.8 (1.45) 16.7–35.2
600 6 38.6 (1.45) 24.1–72.3
0
2
4
6
8
10
12
14
16
18
048 1 2
Time (h)
048 1 2
Time (h)
03 2 4 8 16 64 80 96
Time (h)
P
l
a
s
m
a
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
m
g
 
l
−
1
)
Day1, 100 mg (n = 4)
Day1, 200 mg (n = 3)
Day1, 300 mg (n = 5)
Day1, 400 mg (n = 10)
Day1, 600 mg (n = 12)
Day1, 800 mg (n = 2)
Day7, 100 mg (n = 4)
Day7, 200 mg (n = 3)
Day7, 300 mg (n = 5)
Day7, 400 mg (n = 9)
Day7, 600 mg (n = 12)
Day7, 800 mg (n = 2)
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Figure 2 Mean plasma concentrations of BAY 43-9006 on days 1 (A), 7
(B), and 21 (C).
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ssuppressing apoptosis and supporting angiogenesis (Wang et al,
1996; Erhardt et al, 1999; Schulze et al, 2001; Zhong et al, 2001).
Mice lacking these genes exhibit increased apoptosis and
significant vascular defects (Wojnowski et al, 1997; Huser et al,
2001).
BAY 43-9006 is a novel Raf kinase and VEGFR inhibitor that
targets two mechanisms of tumour development – tumour cell
proliferation and tumour angiogenesis. In this Phase I trial, BAY
43-9006 was well tolerated, with a manageable safety profile. The
MTD was determined as 400mg b.i.d., which is being used in Phase
II studies to further assess safety and efficacy of BAY 43-9006 in a
range of tumour types. A Phase III study is under way in patients
with advanced RCC.
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Table 5 RECIST (Response Evaluation Criteria in Solid Tumours)-defined best response in patients with advanced, refractory solid tumours receiving BAY
43-9006
Starting dose of BAY 43-9006
50mg COMB
(n¼7)
100mg b.i.d.
(n¼4)
200mg b.i.d.
(n¼3)
300mg b.i.d.
(n¼5)
400mg b.i.d.
(n¼10)
600mg b.i.d.
(n¼12)
800mg b.i.d.
(n¼3)
Total
(n¼44)
a
Best response assessed 5 4 2 4 7 9 1 32/44 (73%)
Best response
Partial response 1 1/32 (3%)
Stable disease (all) 2 2 1 3 7 1 16/32 (50%)
6–12 months 1 1 3 1 6/32 (19%)
412 months 2 2/32 (6%)
Progressive disease 3 2 2 3 4 1 0 15/44 (59%)
Time to progression
Median, days (range) 70 (50–86) 65 (55–107) 52 (51–52) 44 (22–106) 63 (24–123) 155 (56–280) 276 69 (22–280)
aTumour response was evaluable in 32 patients.
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